Shamburg News · 8-K filed Nov 12, 2026, 4:15 PM EST

Immix Biopharma Reports Third Quarter 2026 Financial Results and Corporate Progress

IMMX · Immix Biopharma, Inc.

  • Earnings
  • Leadership change
  • Materiality: high

On November 12, 2026, Immix Biopharma, Inc. reported financial results for the quarter ended September 30, 2026, with a net loss of $13.9 million for the three months and $340.9 million in cash, cash equivalents and marketable securities at quarter end. The company also reported that interim NEXICART-2 clinical results will be presented at the ASH 2026 Annual Meeting on December 14, 2026, and announced the appointments of David He, MD, PhD and Karin McIntosh as senior vice presidents. The press release did not report per-share earnings or revenue figures.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001493152-26-051402.

Written from the filing by Shamburg Markets. Figures are as reported by the company.